Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)
ID: 356437Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $150K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356437

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-297.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Imaging - Science Track Award for Research Transition (I/START)" aimed at advancing neuroimaging methodologies relevant to substance use disorder (SUD) research. This program encourages both new and established investigators to conduct small "proof-of-concept" studies within a one-year project period, with a funding ceiling of $150,000. The initiative is designed to lower barriers for researchers in adopting advanced imaging techniques, thereby contributing to significant advancements in understanding and addressing substance use challenges. Interested applicants can find more information and application details at the provided link, with the application deadline set for January 7, 2028.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-297.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA), is issuing a funding opportunity titled "Imaging - Science Track Award for Research Transition (I/START)." This program encourages small research grant applications aimed at advancing neuroimaging methodologies relevant to substance use disorder (SUD) research. The initiative is designed to support both new and established investigators in conducting "proof of concept" studies within a one-year project period, with a budget of up to $150,000. Key components of the program include a focus on the development and application of molecular imaging tools, facilitating the understanding of central nervous system (CNS) dysfunction related to SUD. The announcement specifies eligible applicants, comprising various educational institutions and organizations, including those from underrepresented groups. Additionally, it outlines application procedures, eligibility requirements, funding restrictions, and review criteria for assessing scientific merit. The I/START program aims to lower barriers for researchers in adopting advanced imaging techniques, ultimately contributing to significant advances in understanding and addressing substance use and its associated challenges.
    Similar Opportunities
    D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering the D-START: Data Science Track Award for Research Transition (D/START) under the R03 Small Grant Program, aimed at funding projects that utilize advanced data science techniques to investigate substance use and substance use disorders (SUD). This opportunity encourages new and established researchers to apply innovative methodologies to address critical questions in addiction research, with a focus on small-scale projects that can provide preliminary data for larger studies. The program is particularly designed to foster collaborations from underrepresented groups in STEM and aims to expedite the development of robust research programs in addiction-related data science. Applicants can request budgets of up to $100,000 for a maximum of two years, with a total of six to seven awards available, amounting to $1 million per year for fiscal years 2025 to 2027. Interested parties should submit their applications electronically through Grants.gov by the closing date of September 7, 2027, and can direct inquiries to grantsinfo@nih.gov.
    D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the D-START: Data Science Track Award for Research Transition (D/START), a federal grant aimed at supporting small research projects that utilize advanced data science techniques to address critical issues related to substance use and substance use disorders. This funding opportunity encourages investigators, particularly those newly entering the field or established researchers incorporating novel methodologies, to propose projects that can be executed quickly and efficiently, including pilot studies and secondary analyses of existing datasets. Grants of up to $100,000 per project per year are available for a maximum of two years, with a total of six to seven awards anticipated annually. Interested applicants should adhere to the application guidelines outlined in the NIH Application Guide, with the earliest submission date set for September 16, 2024, and applications due by 5:00 PM local time. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)" aimed at encouraging clinical research to identify and validate novel targets for non-invasive brain stimulation (NIBS) related to substance use disorders (SUD). This initiative seeks exploratory and developmental studies that may involve significant risks but have the potential to lead to breakthroughs in understanding the neurobiological and behavioral responses associated with SUD treatment. The funding opportunity includes a budget cap of $600,000 for the R61 phase, with a total of up to $1.5 million available across multiple awards, and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP). Interested applicants should note that the application period opens on December 16, 2023, and closes on August 14, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications that support a diverse range of preclinical and clinical projects, with the goal of advancing medication studies toward FDA approval, emphasizing the importance of innovative approaches to drug misuse and addiction treatment. Eligible applicants include a variety of institutions, such as higher education entities and community organizations, with funding available up to $5 million per year for projects lasting up to three years. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by August 11, 2025.
    Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)" aimed at accelerating the development of innovative devices to treat Substance Use Disorders (SUDs). The initiative seeks proposals that focus on advancing neuromodulatory or neurophysiological devices through various stages of the FDA approval process, with an emphasis on understanding treatment mechanisms and their efficacy. Eligible applicants include a diverse range of organizations, such as academic institutions, nonprofits, and tribal governments, with a maximum budget of $500,000 per year for the UG3 phase, which lasts up to two years before transitioning to the UH3 phase for an additional three years. Applications will open on November 18, 2023, with awards expected to commence by December 2023; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.